Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 nCoV-19 corona virus vaccine (recombinant).
Dermatol Ther
; 34(6): e15141, 2021 11.
Article
in English
| MEDLINE | ID: covidwho-1429610
ABSTRACT
With the present COVID-19 vaccination drive across the world, adverse skin reactions post COVID-19 vaccine is expected. Majority of these reactions seen were transient or local injection site reactions. However, as the larger population is being vaccinated, certain uncommon dermatological presentations including leukocytoclastic vasculitis, pityriasis rosea, and exacerbation of pre-existing autoimmune diseases are now being reported. Among all the COVID-19 vaccines, most of these reactions are seen with messenger ribonucleic acid-based Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) vaccine. We report two cases of leukocytoclastic vasculitis following ChAdOx1 nCoV-19 corona virus vaccine (recombinant) that bring out potential new dermatological manifestations of recombinant corona virus vaccine being administered across the European, South American, and Asian countries. It is important for all health care workers and patients to be aware of the corona virus vaccine associated adverse cutaneous reactions.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Skin Diseases
/
COVID-19
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Language:
English
Journal:
Dermatol Ther
Journal subject:
Dermatology
Year:
2021
Document Type:
Article
Affiliation country:
Dth.15141
Similar
MEDLINE
...
LILACS
LIS